September 2nd 2025
Why the life science industry needs to move away from omnichannel marketing strategies and toward optichannel approaches that boost personalization and ROI in an era of shrinking budgets.
Roche Pulls Out of Agreement With Repare Therapeutics to Develop Novel Cancer Therapy
February 13th 2024Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.